Company Description
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions.
Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jun 25, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 210 |
| CEO | Stephen Gunstream |
Contact Details
Address: 2451 Bert Drive Hollister, California 95023 United States | |
| Phone | (831) 637-1100 |
| Website | teknova.com |
Stock Details
| Ticker Symbol | TKNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001850902 |
| CUSIP Number | 02080L102 |
| ISIN Number | US02080L1026 |
| Employer ID | 94-3368109 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Stephen Gunstream | President, Chief Executive Officer and Director |
| Matthew C. Lowell | Chief Financial Officer |
| Damon A. Terrill | General Counsel, Chief Compliance Officer and Secretary |
| Jennifer Henry | Senior Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 22, 2024 | DEF 14C | Filing |